Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Lipscombe
Date of last notice	29 December 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Direct	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change	Richard John Lipscombe <the a="" c="" luk="" trust=""> Dr Lipscombe is the trustee and a beneficiary of the trust. 28 December 2016</the>	
No. of securities held prior to change	Direct 9,179,692 fully paid ordinary shares ("Shares") 1,632,423 options exercisable at \$0.20 each on or before 31 March 2018 ("Options") 105 Performance Rights Indirect 7,061,589 Shares 1,752,898 Options	
Class	Shares	
Number acquired	12,500 Shares	

⁺ See chapter 19 for defined terms.

Number disposed	Nil.
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$3,155 (\$0.25 per Share)
No. of securities held after change	Direct 9,192,192 Shares 1,632,423 Options 105 Performance Rights Indirect 7,061,589 Shares 1,752,898 Options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

⁺ See chapter 19 for defined terms.

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Terry Sweet
Date of last notice	29 December 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Indirect.	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change	Sparrow Holdings Pty Ltd <sweet fund="" super=""> Mr Sweet is a beneficiary of the superannuation fund and a director and shareholder of the trustee 28 December 2016</sweet>	
No. of securities held prior to change	1,085,500 fully paid ordinary shares ("Shares") 2,758,875 options exercisable at \$0.20 each on or before 31 March 2018 ("Options").	
Class	Shares	
Number acquired	12,500	
Number disposed	Nil.	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$3,000 (\$0.24 per Share)	

⁺ See chapter 19 for defined terms.

No. of securities held after change	1,098,000 Shares 2,758,875 Options.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed	No.
above traded during a +closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade	
to proceed during this period?	
If prior written clearance was provided, on what date was this	
provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	John Dunlop
Date of last notice	29 December 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Randolph Resources Pty Ltd Mr Dunlop is a director and shareholder of the company.
Date of change	28 December 2016
No. of securities held prior to change	Direct 3,855,188 fully paid ordinary shares ("Shares") 28 performance rights Indirect 1,550,000 Shares 375,000 options exercisable at \$0.20 each on or before 31 March 2018 ("Options")
Class	Shares
Number acquired	24,000 Shares
Number disposed	Nil.

⁺ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$6,060 (\$0.25 per Share)
No. of securities held after change	Direct 3,855,188 Shares 28 performance rights Indirect 1,574,000 Shares 375,000Options.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed	No.
above traded during a *closed period where prior written	
clearance was required?	

⁺ See chapter 19 for defined terms.

If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ian Roger Moore
Date of last notice	29 December 2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Direct or indirect interest	Indirect.
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Moore and Sotomi Investments Pty Ltd <roger a="" c="" family="" moore=""></roger>
	Mr Moore is a director and shareholder of
	the trustee and a beneficiary of the trust.
Date of change	30 December 2016
No. of securities held prior to change	175,000 fully paid ordinary shares ("Shares")
Class	Shares
Number acquired	12,000 Shares
Number disposed	Nil.
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$3,018 (\$0.25 per Share)
No. of securities held after change	187,000 Shares.

⁺ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable.
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.